Will Shorter EU Regulatory Timelines Mean Unfeasible Joint Clinical Assessment Timelines?
Executive Summary
Faster regulatory reviews proposed in the European Commission’s pharmaceutical reform package could impact the EU-level joint clinical assessments that go live from 2025.
You may also be interested in...
EU’s Plans for Regulatory Data Protection ‘Unworkable’
The European Commission will have a fight on its hands when it comes to the data protection part of its proposals for EU pharma legislative reform.
The Implications Of The New EU HTA Regulation For Companies
Legal and industry expert Alexander Natz sets out key questions and answers to help companies prepare for new EU regulations on health technology assessments, one of the biggest developments to affect the pharmaceutical industry in over a decade.
Belgium Aims To Drive Biologic Competition Through Tendering
New tendering rules in Belgium aim to improve competition between biosimilars and originators, for example by setting contract durations for tendering contracts and limiting the criteria for such contracts.